Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 310 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Advanced HER2 Positive Breast Carcinoma Clear all
Terminated Phase 1 Interventional

Phase I Study of the Combination of MLN9708 and Fulvestrant

NCT02384746
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, MLN9708
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 13, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy

NCT00803556
View directory record Official record
Conditions
Solid Tumor, Breast Cancer
Interventions
Alvespimycin, Trastuzumab, Paclitaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 13, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

NCT00876395
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Placebo, Trastuzumab, Paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
25
States / cities
Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 13, 2026, 10:23 PM EDT
Terminated Phase 1 Interventional

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

NCT05511844
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
Interventions
ORM-5029
Drug
Lead sponsor
Orum Therapeutics USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 13, 2026, 10:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

NCT05230810
View directory record Official record
Conditions
HER2-positive Metastatic Breast Cancer
Interventions
Alpelisib, Tucatinib, Fulvestrant
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Aurora, Colorado • Fort Collins, Colorado • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 13, 2026, 10:23 PM EDT
Recruiting Phase 2 Interventional

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT05969860
View directory record Official record
Conditions
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma, Advanced Carcinoid Tumor, Advanced Cervical Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastric Carcinoma, Advanced Glioblastoma, Advanced Head and Neck Carcinoma, Advanced HER2 Positive Breast Carcinoma, Advanced Lung Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Germ Cell Tumor, Advanced Malignant Solid Neoplasm, Advanced Neuroendocrine Carcinoma, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Small Cell Neuroendocrine Carcinoma, Advanced Prostate Carcinoma, Hematopoietic and Lymphoid System Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome, Advanced Basal Cell Carcinoma, Advanced Cholangiocarcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Liver Carcinoma, Advanced Lymphoma, Advanced Malignant Testicular Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Penile Carcinoma, Advanced Primary Malignant Central Nervous System Neoplasm, Advanced Renal Cell Carcinoma, Advanced Sarcoma, Advanced Skin Squamous Cell Carcinoma, Advanced Urethral Carcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma, Advanced Appendix Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Interventions
Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 13, 2026, 10:23 PM EDT
Completed Phase 1 Interventional Results available

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

NCT01097460
View directory record Official record
Conditions
Breast Neoplasms
Interventions
MM-111 + Herceptin
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Oct 13, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer

NCT00915018
View directory record Official record
Conditions
Breast Cancer
Interventions
Neratinib, Trastuzumab, Paclitaxel
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
36
States / cities
Oxnard, California • Santa Rosa, California • Plainville, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 13, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

NCT03822468
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Anastrozole, Letrozole, Goserelin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
14
States / cities
Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 13, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

NCT03685331
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
Interventions
Palbociclib, Olaparib, Fulvestrant
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 13, 2026, 10:23 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

NCT01912963
View directory record Official record
Conditions
HER2-positive Breast Cancer, Metastatic Breast Cancer
Interventions
Pertuzumab, Trastuzumab, eribulin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 13, 2026, 10:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions
rezatapopt, pembrolizumab
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 10:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

NCT07287917
View directory record Official record
Conditions
Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions
AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 13, 2026, 10:23 PM EDT
Active, not recruiting Phase 1 Interventional

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

NCT04042701
View directory record Official record
Conditions
Breast Cancer, Non-small Cell Lung Carcinoma
Interventions
Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 13, 2026, 10:23 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

NCT07405801
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Ribociclib, Fulvestrant, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
Anaheim, California • Palo Alto, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 10:23 PM EDT
Suspended Phase 1 Interventional

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

NCT04650451
View directory record Official record
Conditions
HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression, Solid Tumor, Adult
Interventions
chimeric antigen receptor (CAR) T cell therapy
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Duarte, California • La Jolla, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 13, 2026, 10:23 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661
View directory record Official record
Conditions
Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Ceralasertib, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Positron Emission Tomography, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Irvine, California • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 13, 2026, 10:23 PM EDT
Active, not recruiting Phase 2 Interventional

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

NCT02849496
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography, Questionnaire Administration, X-Ray Imaging
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 13, 2026, 10:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

NCT01273610
View directory record Official record
Conditions
Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services
Interventions
Lapatinib, Trastuzumab, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
8
States / cities
Duarte, California • Lancaster, California • Pasadena, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 13, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT03337724
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Paclitaxel, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 13, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

NCT01976169
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
PD-0332991 and T-DM1
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 13, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT01281150
View directory record Official record
Conditions
Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Hershey, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 13, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

NCT03854903
View directory record Official record
Conditions
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
Interventions
Palbociclib, Bosutinib, Fulvestrant
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 13, 2026, 10:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT07288359
View directory record Official record
Conditions
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Interventions
GVV858, Fulvestrant, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 13, 2026, 10:23 PM EDT